Osteogenesis Imperfecta

This article reviews the emerging literature on the efficacy of denosumab as a treatment for patients with osteogenesis imperfecta (OI). Denosumab improves bone density in adults with osteoporosis. However, a lack of evidence-based research exists to promote the use of denosumab as a current treatment in patients with OI. Denosumab research on bone density in patients with OI is ongoing. The evidence suggests that denosumab use in patients with OI does improve bone density but gives inconsistent results regarding fracture prevention. Further research must establish the dosing and measurable gains of denosumab treatment in OI.